Clinical trials sponsored by Hebei Medical University Fourth Hospital

Phase breakdown

Conditions studied

Recruiting trials led by Hebei Medical University Fourth Hospital

• Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
  NCT05241028 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
  NCT05525767 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)
  NCT06371482 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer
  NCT05578053 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic
  NCT06056115 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
  NCT06435260 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
  NCT06184698 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer
  NCT04159142 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
  NCT04138719 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer
  NCT07635342 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: Female · 1 location
• Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
  NCT06949111 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
  NCT06217185 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer
  NCT06949098 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Common questions

How many trials is Hebei Medical University Fourth Hospital recruiting for?

Hebei Medical University Fourth Hospital is the lead sponsor of 13 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.